IEMASA KOH

Last Updated :2024/12/02

Affiliations, Positions
Graduate School of Biomedical and Health Sciences(Medical), Associate Professor or Lecturer
E-mail
iemasakohiroshima-u.ac.jp
Self-introduction
I am specialising in gynecologic oncology

Basic Information

Major Professional Backgrounds

  • 2005/04/20, 2005/06/30, Hiroshima University, Hospital, Clinical Resident
  • 2011/04/01, 2011/09/30, Hiroshima University, Hospital, Clinical Fellow
  • 2016/06/01, 2020/01/31, Hiroshima University, Hospital, Assistant Professor
  • 2020/02/01, 2021/09/30, Hiroshima University, Hospital, Lecturer
  • 2021/10/01, Hiroshima University, Graduate School of Biomedical and Health Sciences, Lecturer

Educational Backgrounds

  • Showa University, Japan, 1999/04, 2005/03
  • Hiroshima University, Graduate School of Biomedical Sciences, Japan, 2011/10, 2016/05

Academic Degrees

  • Hiroshima University

Educational Activity

  • [Bachelor Degree Program] School of Medicine : Program of Medicine : Medicine
  • [Master's Program] Graduate School of Biomedical and Health Sciences : Division of Integrated Health Sciences
  • [Doctoral Program] Graduate School of Biomedical and Health Sciences : Division of Biomedical Sciences : Program of Medicine

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical surgery;Obstetrics and gynecology

Research Keywords

  • ovarian cancer, drug resistance

Affiliated Academic Societies

  • Japan Society of Clinical Oncology
  • Japan Society of Obstetrics and Gynecology
  • Japan Society of Gynecologic Oncology
  • Japanese Cancer Association

Educational Activity

Course in Charge

  1. 2024, Undergraduate Education, Year, Systemic Disease Control
  2. 2024, Undergraduate Education, Intensive, Practice of Medicine I

Research Activities

Academic Papers

  1. ★, Regulation of multidrug resistance 1 expression by CDX2 in ovarian mucinous adenocarcinoma, Cancer Medicine, 5(7), 1546-1555, 2016
  2. Concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of the cervix in a uterus didelphys with vaginal septum, JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 11(2), 180-188, 2019
    Link to Paper Search Results by DOI
  3. Regulation of REG4 Expression and Prediction of 5-Fluorouracil Sensitivity by CDX2 in Ovarian Mucinous Carcinoma, CANCER GENOMICS & PROTEOMICS, 16(6), 481-490, 2019
    Link to Paper Search Results by DOI
  4. Indoleamine 2,3-dioxygenase and trophoblast invasion in caesarean scar pregnancy: Implications for the aetiopathogenesis of placenta accreta spectrum, JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 138, 202004
    Link to Paper Search Results by DOI
  5. Porphyromonas gingivalis, a cause of preterm birth in mice, induces an inflammatory response in human amnion mesenchymal cells but not epithelial cells, PLACENTA, 99, 21-26, 20200915
    Link to Paper Search Results by DOI
  6. Localization of Indoleamine 2,3-Dioxygenase-1 and Indoleamine 2,3-Dioxygenase-2 at the Human Maternal-Fetal Interface, INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH, 13, 202012
    Link to Paper Search Results by DOI
  7. Predictive Accuracy of Soluble FMS-Like Tyrosine Kinase-1/Placental Growth Factor Ratio for Preeclampsia in Japan: A Systematic Review, HYPERTENSION RESEARCH IN PREGNANCY, 9(1), 1-7, 202102
    Link to Paper Search Results by DOI
  8. NBS1 I171V variant underlies individual differences in chromosomal radiosensitivity within human populations, SCIENTIFIC REPORTS, 11(1), 20211004
    Link to Paper Search Results by DOI
  9. Could the Human Endogenous Retrovirus-Derived Syncytialization Inhibitor, Suppressyn, Limit Heterotypic Cell Fusion Events in the Decidua?, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 22(19), 202110
    Link to Paper Search Results by DOI

Invited Lecture, Oral Presentation, Poster Presentation

  1. An initiative to reintroduce robot-assisted simple hysterectomy, Iemasa Koh, Arisa Nomura, Shina Harimoto, Miho Yahata, Kosuke Nakamoto, Megumi Tsunakake, Hirohiko Morioka, Yuriko Oomori, Yuko Teraoka, Takako Sadakane, Suguru Nosaka, Masaki Sekine, Katsuyuki Tomono, Tomomi Yamazaki, Yurika Mukai, Yoshiki Kudo, 21st APAGE (Asia-Pacific Gynecological Endoscopy), 2021/09/12, Without Invitation, English
  2. Current efficacy of microsatellite instability examination and pembrolizumab use for gynecologic cancer in our department, Iemasa Koh, Arisa Nomura, Nana Nomura, Kosuke Nakamoto, Hirohiko Morioka, Yuriko Oomori, Yuko Teraoka, Takako Sadakane, Suguru Nosaka, Katsuyuki Tomono, Masaki Sekine, Tomomi Yamazaki, Yurika Mukai, Jun Sugimoto, Yoshiki Kudo, The 73rd Annual Congress of Japan Society of Obstetrics and Gynecology, 2021/04/23, Without Invitation, English
  3. Prediction of 5-fluorouracil Sensitivity by CDX2 in Ovarian Mucinous Carcinoma, Iemasa Koh, Suguru Nosaka, Katsuyuki Tomono, Wataru Yasui, Yoshiki Kudo, The 79th Annual Meeting of the Japanese Cancer Association, 2020/10/01, Without Invitation, Japanese
  4. Kinetics of CDX2 and MDR1 protein in ovarian mucinous adenocarcinoma cell lines, Iemasa Koh, Eiji Hirata, Suguru Nosaka, Satoshi Urabe, Takahiro Nobuzane, Hiroshi Miyoshi, Yoshiki Kudo, 15th BIENNIAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY (IGCS 2014), 2014/11/08, Without Invitation, English
  5. Diagnosis and management of uterine myomas, Tomoko Hirakawa, Iemasa Koh, Yuya Nogami, Kimihiro Nishino, International Workshop of Junior Fellows, 2015/04/11, Without Invitation, English
  6. CDX2 Regulates MDR1 gene expression in ovarian mucinous adenocarcinoma cell lines, Iemasa Koh, Eiji Hirata, Suguru Nosaka, Satoshi Urabe, Takahiro Nobuzane, Hiroshi Miyoshi, Yoshiki Kudo, 2015/04/10, Without Invitation, English
  7. CDX2 regulates Multidrug Resistance 1 expression in ovarian mucinous adenocarcinoma, Iemasa Koh, Eiji Hirata, Suguru Nosaka, Satoshi Urabe, Hiroshi Miyoshi, Yoshiki Kudo, 2016/04/22, Without Invitation, English
  8. Examination of 30 cases treated with bevacizumab for gynecologic cancer in our hospital, Iemasa Koh, Eiji Hirata, Suguru Nosaka, Yoshiki Kudo, The 5th Biennial Meeting of Asian Society of Gynecologic Oncology (ASGO), 2017/11/30, Without Invitation, English
  9. Regulation of Reg IV expression and prediction of response to 5-fluorouracil by CDX2 in ovarian mucinous carcinoma, Iemasa Koh, Eiji Hirata, Suguru Nosaka, Yoshiki Kudo, 2018/05/11, Without Invitation, English
  10. Regulation of MDR1 expression and prediction of anticancer drug resistance by CDX2 in ovarian mucinous carcinoma, Iemasa Koh, Eiji Hirata, Suguru Nosaka, Masaki Sekine, Satoshi Urabe, Yoshiki Kudo, 17th IGCS 2018 (International Gynecologic Cancer Society Meeting), 2018/09/15, Without Invitation, English
  11. Examination of 13 cases using Bevacizumab after radiation therapy against gynecology cancer in our hospital, Iemasa Koh, Eiji Hirata, Suguru Nosaka, Tomomi Yamazaki, Satoshi Urabe, Yoshiki Kudo, 2018/10/18, Without Invitation, English
  12. Prediction of anticancer drug resistance by CDX2 in ovarian mucinous carcinoma, Iemasa Koh, Suguru Nosaka, Masaki Sekine, Satoshi Urabe, Eiji Hirata, Yoshiki Kudo, 2019/04/12, Without Invitation, English
  13. Examination of 50 cases using Bevacizumab against gynecology cancer in our hospital, Iemasa Koh, Suguru Nosaka, Masaki Sekine, Tomomi Yamazaki, Satoshi Urabe, Eiji Hirata, Yoshiki Kudo, 2019/10/24, Without Invitation, English
  14. Regulation of the Reg IV by CDX2 in ovarian mucinous adenocarcinoma, Iemasa Koh, Eiji Hirata, Suguru Nosaka, Hiroshi Miyoshi, Yoshiki Kudo, 2017/04/14, Without Invitation, English

External Funds

Acceptance Results of Competitive Funds

  1. KAKENHI(Grant-in-Aid for Early-Career Scientists), 2019, 2021